Eslam Elkhadrawy/LinkedIn
Jan 28, 2026, 11:45
Eslam Elkhadrawy on Heparin-Induced Thrombocytopenia
Eslam Elkhadrawy, Product Specialist at Inspire Pharma Egypt, shared on LinkedIn:
”Heparin-Induced Thrombocytopenia (HIT):
When anticoagulation paradoxically causes thrombosis
HIT is a severe immune-mediated adverse drug reaction in which heparin exposure leads to thrombocytopenia accompanied by a high risk of thrombosis, rather than bleeding.
The condition is driven by IgG antibodies against the heparin–platelet factor 4 (PF4) complex, resulting in platelet activation and excessive thrombin generation.
Key message:
In HIT, thrombocytopenia reflects platelet activation and consumption, not impaired hemostasis.
References
Greinacher A. NEJM, 2015
Warkentin TE. Circulation, 2015”
Stay updated with Hemostasis Today.
-
Mar 13, 2026, 21:19New Canadian Insights on Switching to Longer-Acting Therapy for Hemophilia A – WFH
-
Mar 13, 2026, 21:01Leonardo Roever: Brain Age as a Biomarker of Neuroplasticity and Motor Recovery After Stroke
-
Mar 13, 2026, 20:50William Tembo: Understanding Stroke Through Landmark Clinical Trials
-
Mar 13, 2026, 20:35Jessica Garcia: New Evidence on Thrombin Generation Patterns in Children with Hemophilia A
-
Mar 13, 2026, 20:11Christoph B. Olivier: New Research from Marius Wessinger on Predicting Therapy Success After Pulmonary Embolism
-
Mar 13, 2026, 19:53Wolfgang Miesbach Announces the New English Edition of “Gene Therapy Concepts in the Treatment of Haemophilia”
-
Mar 13, 2026, 17:21Emmanuel J Favaloro: Acquired Hemostasis Disorders Featured in New Issue of Seminars in Thrombosis and Hemostasis
-
Mar 13, 2026, 17:17Paolo Zamboni: New Insights from Australia on Jugular and Azygous Vein Chronic Obstruction
-
Mar 13, 2026, 17:06Srishti Goyal: Can Thalassemia Major Be Prevented?